drugset
drugset / Trial / NCT04481009

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

NCT04481009 ↗

Phase 1/2 Completed 26 enrolled Eucure (Beijing) Biopharma Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts.

Timeline

Start
2020-08-04
Primary completion
2022-05-16
Completion
2022-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Subject YH003 Unknown — Intravenous
Background Gemcitabine Small molecule — —
Background Paclitaxel Small molecule — —

Indications

cancer